scientific

Verofax facilitates Egyptian EU Export with CBAM Compliance and Lifecycle Assessment Solutions

Source Node:
Time Stamp: February 15, 2024 11:49 AM - Modified On: February 15, 2024 - Published By:
Source Cluster:
Republished By Plato

  Egyptian Businessmen's Association (EBA) convenes export symposium on February 9 CAIRO, Feb 15, 2024 - (ACN Newswire) - The Egyptian Businessmen's Association (EBA) convened a symposium on February 9, chaired by Engineer Majd al-Din al-Manzalawi, Secretary-General and Chairman of the Association’s Industry and Scientific Research Committee, to address the challenges and opportunities presented by the Carbon Border Adjustment Mechanism (CBAM), a law governing manufacturing standards for Egyptian exporters. [caption id="attachment_3095647" align="alignnone" width="780"] The Egyptian Businessmen's Association (EBA) convened to discuss the importance of technology in keeping factories compliant with export

Curio and Deep Isolation Sign MOU to Advance Nuclear Waste Disposal Technologies.

Source Node:
Time Stamp: December 7, 2023 3:23 PM - Modified On: December 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Washington, D.C, December 7, 2023 — Curio, a trailblazer in nuclear technology solutions, and Deep Isolation, an innovator in nuclear waste disposal, have entered into a Memorandum of Understanding (MOU) to collectively drive forward the development of advanced technologies for efficient and secure disposal of high-level nuclear waste (HLW). Under this MOU, both Curio and Deep Isolation will mutually collaborate and exchange critical information for the use of Deep Isolation’s Universal Canister System (UCS) and patented directional drilling solution for deep borehole disposal for the isolation and management of HLW

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:22 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating